Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824002362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129510254510080 |
|---|---|
| author | A.E. Yung Y.J. Jeong A.H. Varey S.N. Lo R. Gupta R. Wu M. Dunn J.H. Lee T.-H.H. Low K.F. Shannon J.R. Clark S. Ch'ng |
| author_facet | A.E. Yung Y.J. Jeong A.H. Varey S.N. Lo R. Gupta R. Wu M. Dunn J.H. Lee T.-H.H. Low K.F. Shannon J.R. Clark S. Ch'ng |
| author_sort | A.E. Yung |
| collection | DOAJ |
| format | Article |
| id | doaj-art-3b40c28d92bd451ea0f67d3bcc89db98 |
| institution | OA Journals |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-3b40c28d92bd451ea0f67d3bcc89db982025-08-20T02:32:57ZengElsevierEJC Skin Cancer2772-61182024-01-01210024810.1016/j.ejcskn.2024.100248Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor ImmunotherapyA.E. Yung0Y.J. Jeong1A.H. Varey2S.N. Lo3R. Gupta4R. Wu5M. Dunn6J.H. Lee7T.-H.H. Low8K.F. Shannon9J.R. Clark10S. Ch'ng11University of Sydney, Sydney, AustraliaRoyal Prince Alfred Hospital, Sydney, AustraliaMelanoma Institute Australia, Sydney, Australia; Westmead Private Hospital, Sydney, AustraliaUniversity of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, AustraliaUniversity of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaChris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaChris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaChris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaChris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaMelanoma Institute Australia, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaUniversity of Sydney, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, AustraliaUniversity of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, Australiahttp://www.sciencedirect.com/science/article/pii/S2772611824002362 |
| spellingShingle | A.E. Yung Y.J. Jeong A.H. Varey S.N. Lo R. Gupta R. Wu M. Dunn J.H. Lee T.-H.H. Low K.F. Shannon J.R. Clark S. Ch'ng Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy EJC Skin Cancer |
| title | Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy |
| title_full | Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy |
| title_fullStr | Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy |
| title_full_unstemmed | Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy |
| title_short | Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy |
| title_sort | survival outcomes in t3n0 versus n1 in head and neck cutaneous squamous cell carcinoma implications for neoadjuvant immune checkpoint inhibitor immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824002362 |
| work_keys_str_mv | AT aeyung survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT yjjeong survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT ahvarey survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT snlo survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT rgupta survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT rwu survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT mdunn survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT jhlee survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT thhlow survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT kfshannon survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT jrclark survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy AT schng survivaloutcomesint3n0versusn1inheadandneckcutaneoussquamouscellcarcinomaimplicationsforneoadjuvantimmunecheckpointinhibitorimmunotherapy |